+ Site Statistics
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

RB-pathway disruption in breast cancer: differential association with disease subtypes, disease-specific prognosis and therapeutic response

RB-pathway disruption in breast cancer: differential association with disease subtypes, disease-specific prognosis and therapeutic response

Cell Cycle 9(20): 4153-4163

In breast cancer, inactivation of the RB tumor suppressor gene is believed to occur via multiple mechanisms to facilitate tumorigenesis. However, the prognostic and predictive value of RB status in disease-specific clinical outcomes has remained uncertain. We investigated RB pathway deregulation in the context of both ER-positive and ER-negative disease using combined microarray datasets encompassing over 900 breast cancer patient samples. Disease-specific characteristics of RB pathway deregulation were investigated in this dataset by evaluating correlation among pathway genes as well as differential expression across patient tumor populations defined by ER status. Survival analysis among these breast cancer samples demonstrates that the RB-loss signature is associated with poor disease outcome within several independent cohorts. Within the ER-negative subpopulation, the RB-loss signature is associated with improved response to chemotherapy and longer relapse-free survival. Additionally, while individual genes in the RB target signature closely reproduce its prognostic value, they also serve to predict and monitor response to therapeutic compounds, such as the cytostatic agent PD-0332991. These results indicate that the RB-loss signature expression is associated with poor outcome in breast cancer, but predicts improved response to chemotherapy based on data in ER-negative populations. While the RB-loss signature, as a whole, demonstrates prognostic and predictive utility, a small subset of markers could be sufficient to stratify patients based on RB function and inform the selection of appropriate therapeutic regimens.

(PDF emailed within 0-6 h: $19.90)

Accession: 055333554

Download citation: RISBibTeXText

PMID: 20948315

DOI: 10.4161/cc.9.20.13454

Related references

Breast cancer prognosis signature: linking risk stratification to disease subtypes. Briefings in Bioinformatics: -, 2018

Dietary fat, fat subtypes, and breast cancer risk: lack of an association among postmenopausal women with no history of benign breast disease. Cancer Epidemiology, Biomarkers & Prevention 11(3): 261-265, 2002

Disruption of cell death signaling in cancer: impact on disease prognosis and response to therapy. Current Medicinal Chemistry. Anti-Cancer Agents 3(5): 319-326, 2003

Low penetrance breast cancer susceptibility loci are associated with specific breast tumor subtypes: findings from the Breast Cancer Association Consortium. Human Molecular Genetics 20(16): 3289-3303, 2011

Significance of iodine symporter for prognosis of the disease course and efficacy of neoadjuvant chemotherapy in patients with breast cancer of luminal and basal subtypes. Experimental Oncology 39(1): 65-68, 2017

Differential involvement of RASSF2 hypermethylation in breast cancer subtypes and their prognosis. Oncotarget 6(27): 23944-23958, 2016

Annexin A1 expression in a pooled breast cancer series: association with tumor subtypes and prognosis. Bmc Medicine 13(): 156-156, 2015

Ki-67 can be used for further classification of triple negative breast cancer into two subtypes with different response and prognosis. Breast Cancer Research 13(2): R22-R22, 2012

Peritoneal disease in breast cancer: a specific entity with an extremely poor prognosis. European Journal of Cancer 45(12): 2146-2149, 2009

FOXM1 predicts overall and disease specific survival in muscle-invasive urothelial carcinoma and presents a differential expression between bladder cancer subtypes. Oncotarget 8(29): 47595-47606, 2017

Association of poor prognosis subtypes of breast cancer with estrogen receptor alpha methylation in Iranian women. Asian Pacific Journal of Cancer Prevention 13(8): 4113-4117, 2013

Evaluation of the pathological response and prognosis following neoadjuvant chemotherapy in molecular subtypes of breast cancer. Oncotargets and Therapy 8: 1511-1521, 2015

Molecular subtypes of breast cancer in relation to paclitaxel response and outcomes in women with metastatic disease: results from CALGB 9342. Breast Cancer Research 8(6): R66-R66, 2006

Redefining prognostic factors for breast cancer: YB-1 is a stronger predictor of relapse and disease-specific survival than estrogen receptor or HER-2 across all tumor subtypes. Breast Cancer Research 10(5): R86-R86, 2008

RB-pathway disruption is associated with improved response to neoadjuvant chemotherapy in breast cancer. Clinical Cancer Research 18(18): 5110-5122, 2013